Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zura Bio Limited filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing antibody candidates for autoimmune and inflammatory diseases. Its disclosures include operating and financial results, Regulation FD materials, clinical-program communications, and risk-related context for a multi-asset immunology pipeline led by tibulizumab (ZB-106).
The company’s SEC record also covers proxy governance matters, annual general meeting voting, executive and compensation arrangements, and capital-structure activity involving Class A ordinary shares, pre-funded warrants, underwriting agreements, and related legal opinions. Current reports and proxy materials provide formal disclosure of material events, shareholder matters, and emerging growth company status.
Zura Bio Limited reported a board change. On May 20, 2026, director Someit Sidhu informed the company that he will resign from the board of directors, effective May 21, 2026. The company states that his resignation is not due to any disagreement regarding its operations, policies or practices.
ZURA BIO LIMITED files an amended joint Schedule 13G reporting beneficial ownership positions held by a Venrock-affiliated group as of March 31, 2026. The group and related reporting persons each report 9.99% beneficial ownership, reflecting a capped position of 9,816,384 Class A Ordinary Shares under the Pre-Funded Warrants' Beneficial Ownership Blocker. The percentage is calculated using 94,880,710 Class A Ordinary Shares outstanding as of March 31, 2026 and 3,381,394 Class A Ordinary Shares issuable upon exercise of Pre-Funded Warrants. The filing lists the reporting group members, their shared voting and dispositive powers over 9,816,384 shares, and explains that the Blocker prevents exercises that would exceed the 9.99% threshold.
Zura Bio Limited reports a joint Schedule 13G/A filing disclosing beneficial ownership of 4,215,930 Class A Ordinary Shares, equal to 4.44% of the class. The percentage is calculated using 94,880,710 shares outstanding as of March 19, 2026 as reported in the issuer's Form 10-K.
The filing is made jointly by Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl under a Joint Filing Agreement dated May 15, 2026, and shows shared voting and dispositive power over the reported shares.
Zura Bio Limited Schedule 13G/A (Amendment No. 3) reports beneficial ownership positions held by Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen. The filing shows 9,524,263 shares (9.9%) for Suvretta/Aaron Cowen and 8,372,230 shares (8.8%) for Averill.
The statement discloses that the reported share counts include Class A Ordinary Shares that may be acquired upon exercise of pre-funded warrants with an exercise price of $0.0001, subject to a Maximum Percentage limit (currently 9.99%) and an option for the Fund to increase that cap up to 19.99% (effective after the 61st day following written notice to the issuer). The filing notes the shares are directly owned by advisory clients of Suvretta and that Averill Master Fund, Ltd. is a >5% holder.
Zura Bio Limited reported first quarter 2026 results and highlighted progress on its immunology pipeline. The company is advancing two Phase 2 trials of tibulizumab in hidradenitis suppurativa (TibuSHIELD) and systemic sclerosis (TibuSURE), with topline data expected in Q4 2026 and the first half of 2027, respectively.
Zura closed an underwritten public offering in February 2026 that generated approximately $144 million in gross proceeds, strengthening its balance sheet. Cash and cash equivalents were $225.6 million as of March 31, 2026, which management expects will fund planned operations through at least the end of 2028.
Research and development expenses rose to $14.7 million from $10.5 million a year earlier as tibulizumab programs progressed. General and administrative expenses increased to $10.8 million from $8.8 million, reflecting higher compensation and professional costs. Net loss widened to $24.2 million, or $0.22 per share, compared with $17.4 million, or $0.19 per share, in the first quarter of 2025.
Zura Bio Limited reported a larger net loss as it invested heavily in clinical development while strengthening its balance sheet. For the three months ended March 31, 2026, net loss was $24.2 million compared with $17.4 million a year earlier, driven by higher research and development and administrative costs.
Research and development expenses rose to $14.7 million, mainly from Phase 2 trials of lead antibody tibulizumab in hidradenitis suppurativa and systemic sclerosis. General and administrative expenses increased to $10.8 million as the company expanded its public-company and corporate infrastructure.
Zura closed a February 2026 equity offering of Class A shares and pre-funded warrants, generating net proceeds of about $134.6 million. Cash and cash equivalents grew to $225.6 million, and management believes this should fund operations through at least the end of 2028 while it advances multiple autoimmune and inflammatory disease programs.
Zura Bio Ltd: JPMorgan Chase filed an amended Schedule 13G/A reporting beneficial ownership of 4,471,316 Class A Ordinary Shares, equal to 4.7% of the class as disclosed in Item 4.
The filing lists sole voting power and sole dispositive power over 4,471,316 shares and identifies J.P. Morgan Securities PLC and J.P. Morgan Securities LLC as relevant subsidiaries. The amendment is signed by a JPMorgan vice president.
Zura Bio Limited is asking shareholders to vote at its virtual annual meeting on June 17, 2026, at 12:00 p.m. Eastern Time. Holders of 94,880,710 Class A ordinary shares as of April 20, 2026 can attend online and vote using a control number.
Shareholders will elect eight directors, ratify WithumSmith+Brown, PC as independent auditor for 2026, approve an amended and restated 2023 Equity Incentive Plan, and authorize a potential adjournment to solicit additional proxies. The equity plan amendment keeps the existing share limits but changes the automatic “evergreen” formula so that, starting January 1, 2027, annual share increases can also factor in Class A shares underlying outstanding pre-funded warrants, aligning the pool with the company’s broader economic capitalization.
Zura Bio Limited reported a leadership change in its finance function. On April 20, 2026, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer Eric Hyllengren was separated from the company, with the company stating the separation was not related to its financial or operating results or to any disagreements over operations or reporting practices. Under a Separation Agreement signed April 21, 2026, he will receive severance equal to three months of base salary and reimbursement of COBRA premiums for up to six months, contingent on his compliance with the agreement.
The board appointed Marlyn Mathew, the company’s Vice President, Finance and Accounting, as principal accounting officer and principal financial officer effective April 20, 2026. Her annual base salary was increased to $366,415. Mathew has led finance and accounting at Zura Bio since June 2022 and previously held controller roles at Immunovant. The company notes she has no related‑party arrangements or family relationships with directors or executive officers.